Study of Serum Tumor Markers of HBV Associated HCC

Study Overview
=================
Brief Summary
-----------------
In this study, the investigators will detect the expression of four potential HBV-related HCC biomarkers: PGIR,FAM3C,LAMB1 and SDC4 in tumor tissues and peripheral blood, to explore the specific molecular markers for the early diagnosis of HBV-related HCC.

Detailed Description
-----------------
Paired hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and adjacent liver tissues were selected, and the mRNA and protein expressions of the PGIR,FAM3C,LAMB1 and SDC4 biomarkers in tissues were detected by RT-PCR, western Blot and immunohistochemical analysis. At the same time, healthy subjects were selected as the control group, and mRNA and protein expression levels of the above molecules in blood were detected by RT-PCR and ELISA. At the same time, the correlation between the above biomarkers and the clinical data of patients, such as diagnosis, pathological grading, recurrence, metastasis and survival time was statistically analyzed.

Official Title
-----------------
Study of Serum Tumor Markers of HBV Associated HCC

Conditions
-----------------
HCC

Intervention / Treatment
-----------------
* Diagnostic Test: tumor tissue and blood tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No local or systemic treatment was performed before surgery. The patients were finally diagnosed with HBV-related HCC by examination and imaging examination, and the clinicopathologic data were complete. Exclusion Criteria: Patients with benign liver diseases, such as hepatic cysts and hepatic hemangiomas, or have tumors other than HBV-related HCC.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HBV-associated HCC group<br>The patient was finally diagnosed with HBV-related HCC by examination and imaging examination, and the clinicopathologic data were complete. | Diagnostic Test: tumor tissue and blood tests<br>* In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.<br>|
| negative control group<br>HBV positive but not HCC | Diagnostic Test: tumor tissue and blood tests<br>* In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.<br>|
| Healthy control group<br>Healthy crowd | Diagnostic Test: tumor tissue and blood tests<br>* In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of RNA and protein for diagnosis | Detect the content of the RNA and protein in tumor and serum | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HBV related HCC